2022_Dec_DDL_Edinburgh_leaderboard

CounterAct

CounterAct is developing a nasal delivery device for naloxone in the treatment of opioid overdose. It has completed its pre-IND meeting with the US FDA, has a 505(B)(2) regulatory path mapped, has a US patent granted and has filed international non-provisional patents.


Visit Website

Headquarters
CounterAct
440 S Melrose Drive, #250
Vista
CA 92081
United States

Phone / Contact

T: +1 619 507 7907

Connect

Articles by CounterAct

Top